Stuart Isaacson, MD
Neurology · Boca Raton, FLNPI 1023059169
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,407,392 of the $3,945,934 with a category attached, or 61.0%. It is spread thinly across 42 manufacturers, the largest accounting for just 20.9%. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,123 payments — averaging $1263.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$825K
- Acadia Pharmaceuticals Inc$558K
- Neurocrine Biosciences, Inc.$491K
- Teva Pharmaceuticals USA, Inc.$440K
- Kyowa Kirin, Inc.$331K
- Amneal Pharmaceuticals LLC$303K
- plus $999K from 36 others
Across 1,622 payments — averaging $4253.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$1M
- H. Lundbeck A S$946K
- AbbVie$882K
- Amneal Pharmaceuticals LLC$673K
- Biogen$451K
- UCB SA$406K
- plus $2.5M from 20 others
What the payments were for
- Consulting fees$1,029,86026%
- Speaking & faculty fees$2,407,39261%
- Travel & lodging$290,5887%
- Food & beverage$78,9672%
- Education$139,1274%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,945,934 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 211 | $1,435,114 |
| GocovriAmantadine Hcl | 103 | $369,862 |
| NourianzIstradefylline | 69 | $267,982 |
| RytaryCarbidopa/Levodopa | 220 | $249,529 |
| Droxidopa | 38 | $188,021 |
| InbrijaLevodopa | 22 | $162,187 |
| OngentysOpicapone | 106 | $151,591 |
| NeuproRotigotine | 42 | $54,933 |
| XadagoSafinamide Mesylate | 30 | $54,612 |
| CrexontCarbidopa/Levodopa | 63 | $44,574 |
| Rivastigmine | 96 | $27,942 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 530 | $23,885 |
| Rasagiline Mesylate | 149 | $17,273 |
| Pramipexole ErPramipexole Di-Hcl | 19 | $6,264 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 15 | $2,753 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $558,296 | $1,435,114211 claims |
| MDD US Operations, LLCGocovri | $824,603 | $369,862103 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $302,646 | $294,103283 claims |
| Kyowa Kirin, Inc.Nourianz | $330,946 | $267,98269 claims |
| Acorda Therapeutics, IncInbrija | $260,259 | $162,18722 claims |
| Neurocrine Biosciences, Inc.Ongentys | $490,807 | $151,591106 claims |
| UCB, Inc.Neupro | $776 | $54,93342 claims |
| Almatica Pharma LLCSertraline Hcl | $39 | $66753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Boca Raton
- Brian SteingoBoca Raton$792K
- Richard IsaacsonBoca Raton$127K
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.